So, is it people’s opinion that our efficacy data will be “good, but maybe not great”? NP’s not so good at hiding his emotions - and his mannerisms in interviews don’t suggest that the efficacy data is off the charts. Maybe it’s just me though.
But perhaps we just need good data (vs great) to be off to the races, given that nothing else is working at all.
I guess it just feels like the Montifier (sp?) cases and Patterson’s data, etc set expectations that Leronlimab was a silver bullet against COVID. to me it seems like that expectation that has tempered? But that even if we’re moderately effective that’s still good?
Market Data 
Markets 
AI
